Day: April 24, 2020

FORT LAUDERDALE, Fla., April 24, 2020 (GLOBE NEWSWIRE) — KEMET Corporation (“KEMET”) (NYSE: KEM) today announced that, in connection with the pending acquisition of KEMET by Yageo Corporation (“Yageo”) (TAIEX: 2327), on April 23, 2020, the Committee on Foreign Investment in the United States (CFIUS) notified the parties that it completed review of the pending acquisition of KEMET by Yageo and determined that there are no unresolved national security concerns with respect to the transaction.KEMET today also announced that, on April 15, 2020, the Taiwan Fair Trade Commission (TFTC) announced its approval of the acquisition of KEMET by Yageo. The parties continue to expect the transaction to close in the second half of 2020 with the goal of closing by the end of the third quarter of 2020, subject to additional customary closing conditions...

SAN DIEGO, April 24, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today announced that it has retained global rights to and has sole responsibility for development and commercialization of TRC253 based on Janssen Pharmaceutica N.V.’s (Janssen’s) decision not to exercise its option to reacquire global rights to TRC253 following a review of the Phase 2 data in prostate cancer patients with acquired resistance to Xtandi® or Erleada®.  Under the original agreement, TRACON is obligated to make certain payments to Janssen if future development and regulatory milestones are achieved and to pay a royalty on net sales of TRC253.  TRACON has initiated an out-licensing process to identify a...

MOUNT AIRY, N.C., April 24, 2020 (GLOBE NEWSWIRE) — Surrey Bancorp (the “Company”) (Pink Sheets: SRYB), the holding company for Surrey Bank & Trust (the “Bank”), today reported earnings for the first quarter of 2020.For the quarter ended March 31, 2020, net income totaled $1,056,012 or $0.25 per fully diluted common share, compared with $941,764 or $0.23 per fully diluted common share earned during the first quarter of 2019.Net interest income decreased from $3,246,223 in the first quarter of 2019 to $3,192,503 in 2020. The net interest margin decreased from 4.62 percent in the first quarter of 2019 to 4.19 percent in the first quarter of 2020 due to a general decrease in interest rates and a change in earning asset mix. Higher yielding loans made up 81.8 percent of average interest earning assets in the first quarter of 2019...

SHANGHAI, China and ROCKVILLE, MD., April 24, 2020 (GLOBE NEWSWIRE) — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced its participation in the following conferences in May. Details of the conferences and management presentation are as follows:Bank of America Securities Global Virtual Healthcare ConferencePresentation: Thursday, May 14, 2020 at 9:40-10:10 a.m. ETPresenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR DirectorWebcast...

ATLANTA, April 24, 2020 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report first quarter 2020 financial results on Wednesday, April 29, 2020 after the market close.Management will host a conference call at 9:00 AM ET on Thursday, April 30, 2020, to review financial results and provide an update on corporate developments.  Following management’s formal remarks, there will be a question and answer session.Participants are asked to pre-register for the call through the following link: http://dpregister.com/10142450. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay....

VANCOUVER, British Columbia, April 24, 2020 (GLOBE NEWSWIRE) — The TELUS Friendly Future Foundation today announced a $250,000 donation to support a number of community healthcare leaders in their COVID-19 response for homeless and marginalized citizens across Canada. The funding will bolster efforts to provide a multitude of services, including COVID-19 assessments; triage service at temporary isolation shelters; and personal protective equipment and cleaning supplies to ensure a clean and safe environment for patients and clinicians. With the spread of COVID-19 persisting and more than 235,000 individuals experiencing homelessness in Canada each year, these services are crucial to help vulnerable populations through the pandemic.“During this global health emergency, our team’s unwavering commitment to helping those in our communities...

VANCOUVER, Colombie-Britannique, 24 avr. 2020 (GLOBE NEWSWIRE) — La Fondation TELUS pour un futur meilleur a annoncé aujourd’hui un don de 250 000 $ en vue d’aider des organismes de soins de santé communautaires à intervenir auprès des sans-abri et des citoyens marginalisés à l’échelle du Canada en réponse à la pandémie de COVID-19. Ce financement amplifiera les efforts déployés afin de fournir une multitude de services, notamment des tests de dépistage de la COVID-19, un service de triage et des abris temporaires à des fins d’isolement. De plus, il permettra d’acheter de l’équipement de protection individuelle et des articles de nettoyage afin d’offrir un environnement propre et sécuritaire aux patients et aux cliniciens. Puisque la propagation de la COVID-19 se poursuit et qu’il y a plus de 235 000 sans-abri au Canada chaque année,...

AUSTIN, Texas, April 24, 2020 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Aaron Schuchart will be joining the company as Chief Business Officer starting on May 6, 2020. In this role, Mr. Schuchart will coordinate with Lumos Pharma management and operational teams to identify and advance business development opportunities for the company as part of its strategy to expand its pipeline.“I am delighted to welcome Aaron Schuchart to the Lumos Pharma management team,” said Rick Hawkins, Chairman, CEO and President. “Mr. Schuchart’s years of experience in business development and licensing for biotechnology companies large and small will lend further support to the company’s efforts to advance our strategy to expand its portfolio...

TORONTO, April 24, 2020 (GLOBE NEWSWIRE) — Osisko Mining Inc. (“Osisko” or the “Corporation”) (TSX: OSK) is pleased to announce that it has filed and commenced mailing of the notice of meeting and management information circular in connection with its annual meeting of shareholders (“the Meeting”) to be held on May 29, 2020 at 10:00 a.m. (Toronto time), at the offices of 155 University Avenue, Suite 1440, Toronto, Ontario, Canada, M5H 3B7.In view of the current health risks associated with large public gatherings, due to COVID-19, shareholders are asked to not attend the meeting in person, particularly if they are experiencing any of the described COVID-19 symptoms of fever, cough or difficulty breathing. Instead, shareholders will have an equal opportunity regardless of their geographic location to participate in the Meeting by...

TORONTO, 24 avr. 2020 (GLOBE NEWSWIRE) — Minière Osisko inc. (« Osisko » ou la « Société ») (TSX : OSK) a le plaisir d’annoncer le dépôt et l’envoi par la poste de l’avis de convocation et de la circulaire de sollicitation de procurations en lien avec son assemblée annuelle des actionnaires (l’« assemblée ») qui aura lieu le 29 mai 2020 à 10 h 00 (heure de Toronto), aux bureaux sis au 155 University Avenue, bureau 1440, Toronto, Ontario, Canada, M5H 3B7.Compte tenu des risques sanitaires actuels associés aux grands rassemblements publics, en raison de la COVID-19, les actionnaires sont invités à ne pas se présenter à l’assemblée en personne, particulièrement s’ils présentent l’un ou l’autre des symptômes associés à la COVID-19, soit fièvre, toux ou difficultés respiratoires. En lieu et place, tous les actionnaires auront la possibilité...